CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on August 18, 2023
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
August 18, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
| Re: | Lixte Biotechnology Holdings, Inc. | |
| Registration Statement on Form S-3 | ||
| Filed August 11, 2023 | ||
| File No. 333-273932 |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Lixte Biotechnology Holdings, Inc., a Delaware corporation, respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 4:00 p.m., Eastern Time, on Monday, August 21, 2023, or as soon thereafter as is practicable. Please call our counsel, David Ficksman of TroyGould PC at 310-789-1290 to provide notice of effectiveness.
| Very truly yours, | ||
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. | ||
| By: | /s/ John Kovach | |
| John Kovach | ||
| Chief Executive Officer | ||